Biogenix Molecular, LLC

Running trials

• Recruiting

  A Study of [225Ac]Ac-AKY-2519 in Patients With B7-H3 Expressing Solid Tumors

  NCT07887971· Phase 1· Source

• Recruiting

  A Study of [225Ac]Ac-AKY-2519 in Patients With Metastatic Castration-Resistant Prostate Cancer

  NCT07581184· Phase 1· Source

• Recruiting

  A Study of FG-3246 in Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC)

  NCT06842498· Phase 2· Source

• Recruiting

  A Study of [225Ac]Ac-AKY-1189 in Patients With Solid Tumors

  NCT07020117· Phase 1· Source

• Recruiting

  A Study of LY4257496 in Participants With Cancer (OMNIRAY)

  NCT07114601· Phase 1· Source

• Recruiting

  The Study of 177Lu-TLX591 Plus SOC Versus SOC Alone in Patients With mCRPC (ProstACT Global)

  NCT06520345· Phase 3· Source

• Active, not recruiting

  FPI-2265 (225Ac-PSMA-I&T) for Patients With PSMA-Positive Metastatic Castration-Resistant Prostate Cancer (mCRPC)

  NCT06402331· Phase 2· Source

• Recruiting

  Positron Emission Tomography Using 64Cu-SAR-bisPSMA in Participants With High-risk Prostate Cancer Prior to Radical Prostatectomy

  NCT06056830· Phase 3· Source

• Recruiting

  Anti-tumour Activity of (177Lu) rhPSMA-10.1 Injection

  NCT05413850· Phase 1/2· Source

• Active, not recruiting

  177Lu-PSMA-I&T for Metastatic Castration-Resistant Prostate Cancer

  NCT05204927· Phase 3· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Prostate cancer5 recruiting
• Colorectal cancer2 recruiting
• Head and neck cancer2 recruiting
• Lung cancer2 recruiting
• Bladder cancer1 recruiting
• Triple-negative breast cancer1 recruiting

Researchers

No researcher is linked here yet.

Closed trials

• Recruiting

  A Study of LY4337713 in Participants With FAP-Positive Solid Tumors

  NCT07213791· Phase 1· Source

• Terminated

  A Dosimetry Study of Lutetium (177Lu) rhPSMA-10.1 and Lutetium (177Lu) Vipivotide Tetraxetan (Pluvicto®) in Patients With Non-curative Metastatic Prostate Cancer

  NCT06516510· Early phase 1· Source

• Completed

  A First-in-Human Study to Learn About How BAY3630942 is Distributed and Processed Inside the Body When Given After BAY3547922 and How Safe it is in People With Liver Cancer or Other Select Solid Cancers

  NCT06345001· Phase 1· Source

• Completed

  Copper Cu 64 PSMA I&T PET Imaging in Men With Suspected Recurrence of Prostate Cancer

  NCT06235099· Phase 3· Source

• Terminated

  89Zr-girentuximab for PET Imaging of CAIX Positive Solid Tumors

  NCT05563272· Phase 2· Source